References: 1. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818-900. 2. Teckman JH, Blomenkamp KS. Pathophysiology of alpha-1 antitrypsin deficiency liver disease. In: Borel F, Mueller C, eds. Alpha-1 Antitrypsin Deficiency: Methods and Protocols. Humana Press; 2017:1-8. 3. Stoller JK, Tomashefski J Jr, Crystal RG, et al. Mortality in individuals with severe deficiency of α1-antitrypsin: findings from the National Heart, Lung, and Blood Institute Registry. Chest. 2005;127(4):1196-1204. 4. Craig TJ, Corbett ML, Meadows JA. Improving detection of alpha-1 antitrypsin deficiency: role of the allergist. J Allergy Clin Immunol Pract. 2023;11(8):2348-2354. 5. Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis. 2016;3(3):668-682. 6. Barjaktarevic I, Campos M. Management of lung disease in alpha-1 antitrypsin deficiency: what we do and what we do not know. Ther Adv Chronic Dis. 2021;12:49-63. 7. Esmaili S, Rodriguez Hermosa JL, Centanaro GV, Alvarez-Sala JL, Esmaili I, Rubio MC. Progression and augmentation therapy in PiSZ and PiZZ alpha-1 antitrypsin deficiency: a longitudinal functional and densitometric study. Biomolecules. 2025;15(4):599. doi:10.3390/biom15040599 8. Torres-Durán M, Lopez-Campos JL, Barrecheguren M, et al. Alpha-1 antitrypsin deficiency: outstanding questions and future directions. Orphanet J Rare Dis. 2018;13(1):114. doi:10.1186/s13023-018-0856-9 9. Wang T, Shuai P, Wang Q, et al. α‑1 Antitrypsin is a potential target of inflammation and immunomodulation (Review). Mol Med Rep. 2025;31(4):107. doi:10.3892/mmr.2025.13472  10. Kokturk N, Khodayari N, Lascano J, et al. Lung inflammation in alpha‑1‑antitrypsin deficient individuals with normal lung function. Respir Res. 2023;24(1):40. doi:10.1186/s12931-023-02343-3 11. Mazzuca C, Vitiello L, Travaglini S, et al. Immunological and homeostatic pathways of alpha-1 antitrypsin: a new therapeutic potential. Front Immunol. 2024;15:1443297. doi:10.3389/fimmu.2024.1443297 12. Cazzola M, Stolz D, Rogliani P, Matera MG. α1-Antitrypsin deficiency and chronic respiratory disorders. Eur Respir Rev. 2020;29(155):190073. doi:10.1183/16000617.0073-2019 13. Karatas E, Bouchecareilh M. Alpha 1-antitrypsin deficiency: a disorder of proteostasis-mediated protein folding and trafficking pathways. Int J Mol Sci. 2020;21(4):1493. doi:10.3390/ijms21041493 14. University of Utah Health. Alpha-1 antitrypsin deficiency. Accessed February 6, 2026. https://learn.genetics.utah.edu/content/genetics/alpha1/ 15. Viglio S, Iadarola P, D’Amato M, Stolk J. Methods of purification and application procedures of alpha1 antitrypsin: a long-lasting history. Molecules. 2020;25(17):4014. 16. Abdulkarim A, Craig TJ. Alpha-1 antitrypsin mutation (archived). In: StatPearls [Internet]. StatPearls Publishing; September 26, 2022. Accessed February 20, 2026. https://www.ncbi.nlm.nih.gov/books/NBK482180 17. Kalfopoulos M, Wetmore K, ElMallah MK. Pathophysiology of alpha-1 antitrypsin lung disease. In: Borel F, Mueller C, eds. Alpha-1 Antitrypsin Deficiency: Methods in Molecular Biology. Humana Press; 2017:9-20. 18. Feitosa PHR, de Oliveira Castellano MVC, da Costa CH, et al. Recommendations for the diagnosis and treatment of alpha-1 antitrypsin deficiency. J Bras Pneumol. 2024;50(5):e20240235. doi:10.36416/1806-3756/e20240235 19. Mulkareddy V, Roman J. Pulmonary manifestations of alpha 1 antitrypsin deficiency. Am J Med Sci. 2024;368(1):1-8. 20. Strnad P, McElvaney NG, Lomas DA. Alpha1-antitrypsin deficiency. N Engl J Med. 2020;382(15):1443-1455. 21. COPD Foundation. Genetic COPD. Reviewed April 17, 2025. Accessed July 29, 2026. https://www.copdfoundation.org/Learn-More/I-am-a-Healthcare-Provider/Genetic-COPD.aspx 22. Quinn M, Ellis P, Pye A, Turner AM. Obstacles to early diagnosis and treatment of alpha-1 antitrypsin deficiency: current perspectives. Ther Clin Risk Manag. 2020;16:1243-1255. 23. Global Initiative for Chronic Obstructive Lung Disease (GOLD). GOLD Report. Accessed February 3, 2026. https://goldcopd.org/2026-gold-report-and-pocket-guide/ 24. Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with alpha1-antitrypsin deficiency between 1968 and 2003. Chest. 2005;128(3):1179-1186. 25. Craig TJ, Henao MP. Advances in managing COPD related to α1 – antitrypsin deficiency: an under-recognized genetic disorder. Allergy. 2018;73(11):2110-2121. 26. Demeo DL, Sandhaus RA, Barker AF, et al. Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. Thorax. 2007;62(9):806-813. 27. Tejwani V, Nowacki AS, Fye E, Sanders C, Stoller JK. The impact of delayed diagnosis of alpha-1 antitrypsin deficiency: the association between diagnostic delay and worsened clinical status. Respir Care. 2019;64(8):915-922. 28. Meischl T, Schmid-Scherzer K, Vafai-Tabrizi F, et al. The impact of diagnostic delay on survival in alpha-1-antitrypsin deficiency: results from the Austrian alpha-1 lung registry. Respir Res. 2023;24(1):34. doi:10.1186/s12931-023-02338-0 29. Khandelwal N, Hinson J,Nguyen T, et al. Clinical and economic outcomes in patients with alpha-1 antitrypsin deficiency in a US Medicare advantage population. J Health Econ Outcomes Res. 2025;12(1):66-74. 30. Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. Nat Rev Dis Primers. 2015;1:15010. doi:10.1038/nrdp.2015.10 31. Molloy K, Hersh CP, Morris VB, et al. Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med. 2014;189(4):419-427. 32. McElvaney GN, Sandhaus RA, Miravitlles M, et al. Clinical considerations in individuals with α1-antitrypsin PI*SZ genotype. Eur Respir J. 2020;55(6):1902410 doi:10.1183/13993003.02410-2019

Alpha-1 Antitrypsin Deficiency (AATD)

Latest Articles

Lung Disease in AATD: Potential Pulmonary Manifestations of Below-Normal AAT Levels